Patients With Esophageal Squamous Cell Carcinoma Respond to Camrelizumab/Apatinib Combo in Second-Line Setting
Data presented at the 2021 Gastrointestinal Cancers Symposium shows promise for the combination of camrelizumab plus apatinib for previously treated patients with esophageal squamous cell carcinoma.
Study Finds No Difference in Disease Recurrence Between Tamoxifen, Anastrozole in Postmenopausal Women With DCIS
An analysis of tamoxifen versus anastrozole showed no significant difference in terms of disease recurrence in postmenopausal women with locally excised ductal carcinoma in situ; however, the findings may highlight the understanding of associated toxicities.
Addition of Navitoclax Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis
Study results showed that adding navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.
Enzalutamide Yields PFS Benefit Across nmCRPC Subgroups
Enzalutamide improved progression-free survival and increased time to prostate-specific antigen progression, compared with bicalutamide, in patients with nonmetastatic castration-resistant prostate cancer.
2 Clarke Drive Cranbury, NJ 08512